Mesoblast Stock Net Income
| MEOBF Stock | USD 1.59 0.00 0.00% |
As of the 16th of February 2026, Mesoblast secures the Mean Deviation of 1.22, standard deviation of 5.43, and Risk Adjusted Performance of 0.0635. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mesoblast, as well as the relationship between them. Please verify Mesoblast coefficient of variation, as well as the relationship between the total risk alpha and skewness to decide if Mesoblast is priced some-what accurately, providing market reflects its recent price of 1.59 per share. Please also check out Mesoblast information ratio, which is currently at 0.0553 to check the company can sustain itself at a future point.
Mesoblast's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Mesoblast's valuation are provided below:Mesoblast does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Mesoblast |
Mesoblast 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Mesoblast's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Mesoblast.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Mesoblast on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Mesoblast or generate 0.0% return on investment in Mesoblast over 90 days. Mesoblast is related to or competes with Oxford Nanopore, Neuren Pharmaceuticals, Genus Plc, PeptiDream, CStone Pharmaceuticals, Pharma Mar, and Zur Rose. Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapor... More
Mesoblast Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Mesoblast's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Mesoblast upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0553 | |||
| Maximum Drawdown | 57.06 |
Mesoblast Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mesoblast's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Mesoblast's standard deviation. In reality, there are many statistical measures that can use Mesoblast historical prices to predict the future Mesoblast's volatility.| Risk Adjusted Performance | 0.0635 | |||
| Jensen Alpha | 0.3332 | |||
| Total Risk Alpha | (0.04) | |||
| Treynor Ratio | 0.803 |
Mesoblast February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0635 | |||
| Market Risk Adjusted Performance | 0.813 | |||
| Mean Deviation | 1.22 | |||
| Coefficient Of Variation | 1467.44 | |||
| Standard Deviation | 5.43 | |||
| Variance | 29.49 | |||
| Information Ratio | 0.0553 | |||
| Jensen Alpha | 0.3332 | |||
| Total Risk Alpha | (0.04) | |||
| Treynor Ratio | 0.803 | |||
| Maximum Drawdown | 57.06 | |||
| Skewness | 6.06 | |||
| Kurtosis | 49.89 |
Mesoblast Backtested Returns
Mesoblast appears to be dangerous, given 3 months investment horizon. Mesoblast has Sharpe Ratio of 0.0709, which conveys that the firm had a 0.0709 % return per unit of risk over the last 3 months. We have found sixteen technical indicators for Mesoblast, which you can use to evaluate the volatility of the firm. Please exercise Mesoblast's Standard Deviation of 5.43, mean deviation of 1.22, and Risk Adjusted Performance of 0.0635 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Mesoblast holds a performance score of 5. The company secures a Beta (Market Risk) of 0.45, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Mesoblast's returns are expected to increase less than the market. However, during the bear market, the loss of holding Mesoblast is expected to be smaller as well. Please check Mesoblast's information ratio, and the relationship between the coefficient of variation and skewness , to make a quick decision on whether Mesoblast's current price movements will revert.
Auto-correlation | -0.35 |
Poor reverse predictability
Mesoblast has poor reverse predictability. Overlapping area represents the amount of predictability between Mesoblast time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Mesoblast price movement. The serial correlation of -0.35 indicates that nearly 35.0% of current Mesoblast price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.35 | |
| Spearman Rank Test | -0.15 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Mesoblast reported net income of (91.35 Million). This is 126.77% lower than that of the Healthcare sector and 230.41% lower than that of the Biotechnology industry. The net income for all United States stocks is 116.0% higher than that of the company.
Mesoblast Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mesoblast's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Mesoblast could also be used in its relative valuation, which is a method of valuing Mesoblast by comparing valuation metrics of similar companies.Mesoblast is currently under evaluation in net income category among its peers.
Mesoblast Fundamentals
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0688 | |||
| Operating Margin | (9.53) % | |||
| Current Valuation | 504.31 M | |||
| Shares Outstanding | 736.58 M | |||
| Shares Owned By Insiders | 11.76 % | |||
| Shares Owned By Institutions | 26.13 % | |||
| Price To Earning | (6.34) X | |||
| Price To Book | 0.92 X | |||
| Price To Sales | 68.10 X | |||
| Revenue | 10.21 M | |||
| Gross Profit | (53.36 M) | |||
| EBITDA | (70.3 M) | |||
| Net Income | (91.35 M) | |||
| Cash And Equivalents | 60.45 M | |||
| Cash Per Share | 0.08 X | |||
| Total Debt | 91.62 M | |||
| Debt To Equity | 0.21 % | |||
| Current Ratio | 1.36 X | |||
| Book Value Per Share | 0.71 X | |||
| Cash Flow From Operations | (65.78 M) | |||
| Earnings Per Share | (0.14) X | |||
| Number Of Employees | 77 | |||
| Beta | 2.43 | |||
| Market Capitalization | 544.31 M | |||
| Total Asset | 662.14 M | |||
| Retained Earnings | (288 M) | |||
| Working Capital | 40 M | |||
| Current Asset | 71 M | |||
| Current Liabilities | 31 M | |||
| Z Score | 3.0 | |||
| Net Asset | 662.14 M |
About Mesoblast Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mesoblast's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mesoblast using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mesoblast based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Additional Information and Resources on Investing in Mesoblast Pink Sheet
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more detail on how to invest in Mesoblast Pink Sheet please use our How to Invest in Mesoblast guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.